MIAMI (April 11, 2024) – Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples. The results of the clinical study were published today in Nature Medicine.
This combined approach, developed by Florida International University cancer researcher Diana Azzam, was used successfully for the first time to guide treatment of relapsed pediatric cancer patients in collaboration with First Ascent Biomedical and Dr. Maggie Fader at the Helen & Jacob Shaham Cancer & Blood Disorders Institute at Nicklaus Children’s Hospital in Miami.
It resulted in 83% of the children showing improvement, including Logan Jenner, 8, whose relapsed leukemia was successfully treated through Azzam’s new guided approach.
“The results are exciting because cancer that comes back is much harder to treat. Seeing improvement in 83 percent of patients is incredibly promising,” said Azzam, the assistant professor of environmental health sciences at the FIU Robert Stempel College of Public Health and Social Work and Society for Functional Precision Medicine board member who led the study. “This could be the way we turn cancer into a manageable disease.”
Approximately 2 million people are diagnosed with cancer in the United States each year, according to the National Cancer Institute. Nearly 30 percent (more than 600,000) are expected to die.
Breakthrough approach
The approach Azzam is pioneering has a few advantages over existing precision medicine processes, including faster results and more treatment options for doctors.
Azzam’s approach involves taking a sample of blood or tumor and enriching and processing the cancer cells in the lab in a way that closely resembles how they would normally grow in the body. Then the cancer is exposed to more than 120 FDA-approved drugs, including both cancer and non-cancer drugs. These drugs also may be tested in various combinations recommended by the clinical team. The best cancer destroyers emerge. The entire process takes about a week.
“The Azzam lab approach gets rid of the guesswork and delivers a list of the most effective drugs that the oncologist can work with,” said Stempel College Dean Tomás R. Guilarte, who is also one of the authors of the Nature Medicine article. “It’s accelerating our understanding of which cancer treatments work best for patients and their specific needs.”
Logan’s story
At the age of 3, Logan Jenner was diagnosed with acute myeloid leukemia. He received chemotherapy and bone marrow transplant. The cancer came back 14 months later.
Fader, Logan’s oncologist and co-investigator on the study, enrolled him in the clinical trial.
“What’s unique is that it’s easy and fast to get results about what would be the most optimal regimen, so we can act quickly,” said Fader who is employed by KIDZ Medical Services and cares for patients at Nicklaus Children’s Hospital. “That’s important because we’re talking about a child with cancer getting worse day by day.”
Azzam’s test results revealed which combination of drugs might work well for Logan. Equally valuable, the results indicated that Idarubicin, known to cause cardiac toxicity at very high doses, could be withheld without impacting the efficacy of the treatment. Thirty-three days after starting treatment guided by Azzam’s results, Logan reached remission — compared to the 150 days the previous time. Two years later, Logan remains cancer-free.
The trial returned recommendations for the 19 patients that participated. Six received treatment guided by Azzam’s results and five, including Logan, showed improved survival outcomes over the course of the study.
What’s next
This study is particularly relevant because the majority of the participants were members of ethnic minority populations, who can have different responses to FDA-approved drugs. Azzam also spearheads a National Institute on Minority Health and Health Disparities-funded research project as part of FIU’s Research Center in Minority Institutions to reduce health disparities in childhood cancer patients.
Larger personalized cancer treatment clinical trials for children and adults are ongoing.
With a $2 million appropriation from the State of Florida, Azzam’s lab is set to become the first federally certified large-scale lab dedicated to functional cancer drug testing in Florida.
For more information about Azzam’s research, please click here.
These photos and videos are available for use by media outlets.
Credit: Florida International University
MIAMI (April 11, 2024) – Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples. The results of the clinical study were published today in Nature Medicine.
This combined approach, developed by Florida International University cancer researcher Diana Azzam, was used successfully for the first time to guide treatment of relapsed pediatric cancer patients in collaboration with First Ascent Biomedical and Dr. Maggie Fader at the Helen & Jacob Shaham Cancer & Blood Disorders Institute at Nicklaus Children’s Hospital in Miami.
It resulted in 83% of the children showing improvement, including Logan Jenner, 8, whose relapsed leukemia was successfully treated through Azzam’s new guided approach.
“The results are exciting because cancer that comes back is much harder to treat. Seeing improvement in 83 percent of patients is incredibly promising,” said Azzam, the assistant professor of environmental health sciences at the FIU Robert Stempel College of Public Health and Social Work and Society for Functional Precision Medicine board member who led the study. “This could be the way we turn cancer into a manageable disease.”
Approximately 2 million people are diagnosed with cancer in the United States each year, according to the National Cancer Institute. Nearly 30 percent (more than 600,000) are expected to die.
Breakthrough approach
The approach Azzam is pioneering has a few advantages over existing precision medicine processes, including faster results and more treatment options for doctors.
Azzam’s approach involves taking a sample of blood or tumor and enriching and processing the cancer cells in the lab in a way that closely resembles how they would normally grow in the body. Then the cancer is exposed to more than 120 FDA-approved drugs, including both cancer and non-cancer drugs. These drugs also may be tested in various combinations recommended by the clinical team. The best cancer destroyers emerge. The entire process takes about a week.
“The Azzam lab approach gets rid of the guesswork and delivers a list of the most effective drugs that the oncologist can work with,” said Stempel College Dean Tomás R. Guilarte, who is also one of the authors of the Nature Medicine article. “It’s accelerating our understanding of which cancer treatments work best for patients and their specific needs.”
Logan’s story
At the age of 3, Logan Jenner was diagnosed with acute myeloid leukemia. He received chemotherapy and bone marrow transplant. The cancer came back 14 months later.
Fader, Logan’s oncologist and co-investigator on the study, enrolled him in the clinical trial.
“What’s unique is that it’s easy and fast to get results about what would be the most optimal regimen, so we can act quickly,” said Fader who is employed by KIDZ Medical Services and cares for patients at Nicklaus Children’s Hospital. “That’s important because we’re talking about a child with cancer getting worse day by day.”
Azzam’s test results revealed which combination of drugs might work well for Logan. Equally valuable, the results indicated that Idarubicin, known to cause cardiac toxicity at very high doses, could be withheld without impacting the efficacy of the treatment. Thirty-three days after starting treatment guided by Azzam’s results, Logan reached remission — compared to the 150 days the previous time. Two years later, Logan remains cancer-free.
The trial returned recommendations for the 19 patients that participated. Six received treatment guided by Azzam’s results and five, including Logan, showed improved survival outcomes over the course of the study.
What’s next
This study is particularly relevant because the majority of the participants were members of ethnic minority populations, who can have different responses to FDA-approved drugs. Azzam also spearheads a National Institute on Minority Health and Health Disparities-funded research project as part of FIU’s Research Center in Minority Institutions to reduce health disparities in childhood cancer patients.
Larger personalized cancer treatment clinical trials for children and adults are ongoing.
With a $2 million appropriation from the State of Florida, Azzam’s lab is set to become the first federally certified large-scale lab dedicated to functional cancer drug testing in Florida.
For more information about Azzam’s research, please click here.
These photos and videos are available for use by media outlets.
Journal
Nature Medicine
Method of Research
Observational study
Subject of Research
People
Article Title
Feasibility of Functional Precision Medicine for Guiding Treatment of Relapsed or Refractory Pediatric Cancers
Article Publication Date
11-Apr-2024
COI Statement
Diana Azzam is co-founder and holds shares in First Ascent Biomedical.
